Please assess the completion status of the following clinical trial:

Trial Title: Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females, age ≥18 years~2. Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay~3. On stable antiretroviral therapy for last 12 months~4. Subject has two or more potential alternative antiretroviral regimen options to consider.~5. No documented detectable viral loads (HIV-1 RNA \<50 copies/ml) within the last 12 months prior to Screening Visit~6. Nadir CD4 cell count of \>200 cells/mm3~Exclusion Criteria:~1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay at the Screening Visit~2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)~3. Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition~4. Prior use of any entry, attachment, CCR5 co-receptor, or fusion inhibitor, including PRO 140.~5. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRO 140 (Type: EXPERIMENTAL): PRO 140 350mg weekly SQ injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).